Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Gen Selective PARP1 Inhibitor and ADC November 7, 2023
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions November 7, 2023
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics October 31, 2023
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers October 31, 2023
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs October 25, 2023
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Ph 3 Study of Lisaftoclax + Acalabrutinib in 1L CLL/SLL Patients October 25, 2023
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics October 25, 2023
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for Camrelizumab + Rivoceranib for uHCC October 25, 2023
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA October 25, 2023
MediLink Therapeutics Announces Strategic Collaboration And Worldwide License Agreement With BioNTech To Develop Next-Gen Anti-Cancer ADCs October 18, 2023
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy October 18, 2023
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Gen Radioligand Therapies October 11, 2023
BriaCell Partners with NYCBS for Pivotal Ph3 Study of Bria-IMT in Advanced Breast Cancer October 11, 2023
Ankyra Therapeutics and Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors October 11, 2023
Nektar Therapeutics and Cellular Biomedicine Group to Evaluate NKTR-255 + C-TIL051 in Advanced NSCLC October 3, 2023
AbbVie terminated agreement with Caribou Biosciences regarding development of next-generation, off-the-shelf CAR-T cell therapies October 3, 2023
AbbVie is terminating its agreement with I-Mab to develop certain CD47 antibody compounds, including the programme’s lead drug lemzoparlimab October 3, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® September 26, 2023
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA September 26, 2023
Collaborative Trial to Study PP2A Inhibitor, LB-100, Plus Dostarlimab, in Clear-Cell Ovarian Cancer announced September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Taiho Oncology to Evaluate LYTGOBI + BBI-355 in Patients with FGFR Amplified Solid Tumors September 26, 2023
